Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00VPT
|
|||
| Former ID |
DCL000221
|
|||
| Drug Name |
SB222200
|
|||
| Synonyms |
S 5192; SB 222200; SB-222200; N-(alpha-ethylbenzyl)-3-methyl-2-phenylquinoline-4-carboxamide; (S)-3-Methyl-2-phenyl-N-(1-phenylpropyl)-4-quinolinecarboxamide; 3-methyl-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Schizoaffective disorder [ICD-11: 6A21] | Preclinical | [1], [2] | |
| Schizophrenia [ICD-11: 6A20] | Preclinical | [1], [2] | ||
| Company |
GlaxoSmithKline
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H24N2O
|
|||
| Canonical SMILES |
CCC(C1=CC=CC=C1)NC(=O)C2=C(C(=NC3=CC=CC=C32)C4=CC=CC=C4)C
|
|||
| InChI |
1S/C26H24N2O/c1-3-22(19-12-6-4-7-13-19)28-26(29)24-18(2)25(20-14-8-5-9-15-20)27-23-17-11-10-16-21(23)24/h4-17,22H,3H2,1-2H3,(H,28,29)/t22-/m0/s1
|
|||
| InChIKey |
MQNYRKWJSMQECI-QFIPXVFZSA-N
|
|||
| CAS Number |
CAS 174635-69-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
11111807, 11114060, 11646426, 14927097, 17404663, 24278254, 26732637, 43223799, 46500403, 47870818, 50104836, 50104837, 53777206, 77693440, 90341726, 92303495, 103046613, 103170209, 103948293, 114637120, 121147439, 121360866, 124749447, 124800307, 124881455, 124881456, 124881457, 124881458, 124881459, 128633500, 134346203, 135262014, 135650991, 135698229, 136367791, 137010341, 143156212, 152344470, 162022854, 162248299, 163122207, 163564054, 179235919, 196370284, 204360504, 210275303, 210280952, 223490642, 225135727, 229152082
|
|||
| ChEBI ID |
CHEBI:92079
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neuromedin-K receptor (TACR3) | Target Info | Antagonist | [3], [4], [5] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Reactome | G alpha (q) signalling events | |||
| WikiPathways | Gastrin-CREB signalling pathway via PKC and MAPK | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2131). | |||
| REF 2 | Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist. J Pharmacol Exp Ther. 2000 Oct;295(1):373-81. | |||
| REF 3 | Evidence for mediation of nociception by injection of the NK-3 receptor agonist, senktide, into the dorsal periaqueductal gray of rats. Psychopharmacology (Berl). 2009 May;204(1):13-24. | |||
| REF 4 | Neurokinin B/NK3 receptors exert feedback inhibition on L-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease. Neuropharmacology. 2008 Jun;54(7):1143-52. | |||
| REF 5 | Substance P depolarizes striatal projection neurons and facilitates their glutamatergic inputs. J Physiol. 2008 Apr 15;586(8):2143-55. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.